Role of disease risk scores in comparative effectiveness research with emerging therapies.

Pharmacoepidemiology and Drug Safety
Robert J GlynnSebastian Schneeweiss

Abstract

Usefulness of propensity scores and regression models to balance potential confounders at treatment initiation may be limited for newly introduced therapies with evolving use patterns. To consider settings in which the disease risk score has theoretical advantages as a balancing score in comparative effectiveness research because of stability of disease risk and the availability of ample historical data on outcomes in people treated before introduction of the new therapy. We review the indications for and balancing properties of disease risk scores in the setting of evolving therapies and discuss alternative approaches for estimation. We illustrate development of a disease risk score in the context of the introduction of atorvastatin and the use of high-dose statin therapy beginning in 1997, based on data from 5668 older survivors of myocardial infarction who filled a statin prescription within 30 days after discharge from 1995 until 2004. Theoretical considerations suggested development of a disease risk score among nonusers of atorvastatin and high-dose statins during the period 1995-1997. Observed risk of events increased from 11% to 35% across quintiles of the disease risk score, which had a C-statistic of 0.71. The score a...Continue Reading

References

Mar 1, 1979·Journal of Epidemiology and Community Health·M C PikeN Day
Dec 1, 1976·American Journal of Epidemiology·O S Miettinen
Jul 13, 1974·Lancet·G Teasdale, B Jennett
Mar 1, 1969·Zeitschrift für Ernährungswissenschaft·C Roberts, M Flores
Apr 1, 1984·Statistics in Medicine·F E HarrellR A Rosati
Feb 12, 1998·Annals of Internal Medicine·D B Rubin
Feb 7, 1998·Medical Care·A ElixhauserR M Coffey
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Aug 24, 1999·American Journal of Epidemiology·M M Joffe, P R Rosenbaum
Nov 5, 1999·Journal of the National Cancer Institute·M H GailV Vogel
Sep 13, 2003·Health Services Research·Sebastian SchneeweissRobert J Glynn
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Aug 13, 2004·The New England Journal of Medicine·Pim van der HarstDirk J van Veldhuisen
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Aug 25, 2005·Statistics in Medicine·B I GraubardJoseph L Gastwirth
Apr 14, 2006·Basic & Clinical Pharmacology & Toxicology·Robert J GlynnTil Stürmer
Apr 21, 2006·American Journal of Epidemiology·M Alan BrookhartTil Stürmer
Sep 22, 2007·The American Journal of Cardiology·Soko SetoguchiWolfgang C Winkelmayer
Dec 20, 2007·Epidemiology·Patrick G ArbogastWayne A Ray
Sep 17, 2009·Pharmacoepidemiology and Drug Safety·Suzanne M CadaretteTil Stürmer
Aug 4, 2010·Pharmacoepidemiology and Drug Safety·Sebastian Schneeweiss
Jan 7, 2011·Journal of Clinical Epidemiology·Joshua J GagneSebastian Schneeweiss
May 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew N FreedmanWorta McCaskill-Stevens
Oct 26, 2011·American Journal of Epidemiology·Jessica A MyersRobert J Glynn
Oct 29, 2011·American Journal of Epidemiology·Judea Pearl

❮ Previous
Next ❯

Citations

Aug 2, 2013·BMC Medical Research Methodology·Etsuji SuzukiEiji Yamamoto
Nov 6, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Patrick B RyanDavid Madigan
Nov 4, 2015·Journal of Comparative Effectiveness Research·Mina TadrousSuzanne M Cadarette
Nov 23, 2012·Pharmacoepidemiology and Drug Safety·Mina TadrousSuzanne M Cadarette
May 3, 2014·Pharmacoepidemiology and Drug Safety·Joshua J GagneSebastian Schneeweiss
Oct 6, 2015·Epidemiology·Amand F SchmidtUNKNOWN GetReal Consortium
Apr 3, 2016·BMC Medical Research Methodology·David HajageYann De Rycke
Apr 3, 2016·American Journal of Epidemiology·John G Connolly, Joshua J Gagne
Mar 5, 2016·Journal of Clinical Epidemiology·Hiraku KumamaruSebastian Schneeweiss
Apr 8, 2016·Emerging Themes in Epidemiology·Hiraku KumamaruJoshua J Gagne
Aug 4, 2015·American Journal of Epidemiology·Jessica M FranklinSebastian Schneeweiss
Jun 27, 2015·Pharmacoepidemiology and Drug Safety·Richard WyssTil Stürmer
Mar 31, 2015·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Mark D DaneseGeoffrey A Block
Sep 18, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Joshua J GagneSebastian Schneeweiss
Feb 15, 2018·Pharmacoepidemiology and Drug Safety·Shirley V WangMartin Kulldorff
Nov 11, 2017·Diabetes Care·Sengwee TohUNKNOWN Mini-Sentinel Saxagliptin-AMI Surveillance Writing Group
Jul 6, 2018·Journal of Child and Adolescent Psychopharmacology·Mehmet BurcuGeoffrey L Rosenthal
Jul 20, 2018·Pharmacoepidemiology and Drug Safety·Kazuki YoshidaSengwee Toh
Aug 29, 2018·Diabetes Care·Antonios DourosLaurent Azoulay
Dec 5, 2018·JAMA : the Journal of the American Medical Association·Wayne A RayC Michael Stein
Nov 6, 2018·Clinical Transplantation·Chao ChenJerry McCauley
Feb 16, 2019·Circulation. Cardiovascular Quality and Outcomes·Sebastian SchneeweissKrista F Huybrechts
Feb 7, 2019·American Journal of Epidemiology·David B RichardsonStephen R Cole
Jan 18, 2019·Statistics in Medicine·Tri-Long Nguyen, Thomas P A Debray
Sep 21, 2013·Clinical Journal of the American Society of Nephrology : CJASN·Geoffrey A BlockMark D Danese
May 11, 2012·Pharmacoepidemiology and Drug Safety·Sebastian SchneeweissScott R Smith
Jul 13, 2019·Pharmacoepidemiology and Drug Safety·Rishi J DesaiUNKNOWN Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) Switching Workgroup
Dec 7, 2019·Epidemiology·David B RichardsonAlan C Kinlaw
Feb 6, 2020·Statistics in Medicine·Tri-Long NguyenThomas P A Debray
Jul 16, 2020·Diabetologia·Mugdha GokhaleJohn B Buse
Apr 30, 2020·American Journal of Epidemiology·David B RichardsonStephen R Cole

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.